Aquestive licenses LIBERVANT seizure-cluster film to Eton for $10M upfront, up to $47.5M milestones

Aquestive Therapeutics, Inc.

Aquestive received a $10.0M upfront license fee from Eton for exclusive U.S. rights to LIBERVANT (diazepam) buccal film for epilepsy seizure clusters.
Up to $47.5M milestones: $10M at first U.S. commercial sale (cut to $5M absent full FDA approval for ages 2-5), $2.5M for ages 6-11, $35M on net sales.
Aquestive also gets mid-teens royalties on U.S. net sales and serves as exclusive manufacturer under a 20-year supply agreement.
LIBERVANT holds FDA tentative approval; full approval for ages 12+ expected after VALTOCO orphan exclusivity lapses Jan 10, 2027; launch targeted April 2027.
Type 9 NDA to add ages 6-11 has a PDUFA date of March 29, 2027; U.S. seizure rescue market exceeds $450M annually.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.